 Salarius Pharmaceuticals Inc NASDAQ: SLRX has initiated an investigator-initiated Phase 12 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an open-label, dose-finding, dose-expansion study to determine the maximum tolerated dose and the safety tolerability of seclidemstat in combination with azacytidine for Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. 